Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Sells $109,800.00 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Michael Secora sold 15,000 shares of the stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $7.32, for a total transaction of $109,800.00. Following the transaction, the chief financial officer now owns 1,292,218 shares in the company, valued at $9,459,035.76. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Michael Secora also recently made the following trade(s):

• On Thursday, June 13th, Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.32, for a total transaction of $139,800.00.
• On Wednesday, April 17th, Michael Secora sold 23,124 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $7.58, for a total value of $175,279.92.

Recursion Pharmaceuticals Stock Up 8.9 %

Shares of NASDAQ RXRX opened at $8.36 on Friday. The firm’s 50-day moving average price is $8.71 and its two-hundred day moving average price is $9.77. Recursion Pharmaceuticals, Inc. has a 52-week low of $4.97 and a 52-week high of $16.75. The stock has a market capitalization of $1.99 billion, a P/E ratio of -5.22 and a beta of 0.83.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.04. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. The business had revenue of $13.80 million during the quarter, compared to analyst estimates of $11.10 million. During the same quarter in the previous year, the firm posted ($0.34) EPS. The business’s revenue for the quarter was up 14.0% compared to the same quarter last year. As a group, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. ARK Investment Management LLC lifted its position in Recursion Pharmaceuticals by 200.4% in the 4th quarter. ARK Investment Management LLC now owns 20,654,287 shares of the company’s stock valued at $203,651,000 after purchasing an additional 13,777,689 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Recursion Pharmaceuticals by 2.2% in the first quarter. Vanguard Group Inc. now owns 16,014,764 shares of the company’s stock valued at $159,667,000 after purchasing an additional 349,554 shares during the period. Mubadala Investment Co PJSC bought a new stake in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $128,041,000. Kinnevik AB publ raised its holdings in shares of Recursion Pharmaceuticals by 14.4% during the second quarter. Kinnevik AB publ now owns 11,905,668 shares of the company’s stock valued at $89,293,000 after buying an additional 1,500,000 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. grew its holdings in Recursion Pharmaceuticals by 12.6% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,362,803 shares of the company’s stock worth $103,317,000 after buying an additional 1,159,023 shares in the last quarter. Institutional investors own 89.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on RXRX shares. KeyCorp reduced their target price on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday. Needham & Company LLC restated a “buy” rating and set a $17.00 price objective on shares of Recursion Pharmaceuticals in a research note on Tuesday, June 25th.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.